Cargando…

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS. However, tocilizumab and siltuximab are expensive and some patients fail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lina, Wang, Shuai, Xu, Ji, Zhang, Run, Zhu, Han, Wu, Yujie, Zhu, Liying, Li, Jianyong, Chen, Lijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893957/ https://www.ncbi.nlm.nih.gov/pubmed/33608054 http://dx.doi.org/10.1186/s40164-021-00209-2

Ejemplares similares

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
por: Hu, Yongxian, et al.
Publicado: (2016)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
por: Xia, Yuan, et al.
Publicado: (2022)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion
por: Bottari, Gabriella, et al.
Publicado: (2020)

Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report
por: Zhang, Lan, et al.
Publicado: (2022)

Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
por: Lai, Xun, et al.
Publicado: (2020)

Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?
por: Dave, Prashil, et al.
Publicado: (2021)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T‐cell therapy
por: Nakamura, Naokazu, et al.
Publicado: (2022)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
por: Riegler, Lara L, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
por: Siegler, Elizabeth L., et al.
Publicado: (2020)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
por: Guo, Hanfei, et al.
Publicado: (2022)

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome
por: Jiang, Ying, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
por: Xiao, Bu-Fan, et al.
Publicado: (2021)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Etanercept in the Treatment of Generalized Annular Pustular Psoriasis
por: Lo Schiavo, Ada, et al.
Publicado: (2012)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
por: Zhang, Hao, et al.
Publicado: (2021)

Perispinal etanercept: Potential as an Alzheimer therapeutic
por: Griffin, W Sue T
Publicado: (2008)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
por: Zou, Yixin, et al.
Publicado: (2018)

Therapeutic options in peripheral T cell lymphoma
por: Zhang, Yaping, et al.
Publicado: (2016)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release
por: Liu, Xuan, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy
por: Franke, Anna-Katharina, et al.
Publicado: (2022)

Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome
por: Faqihi, Fahad, et al.
Publicado: (2020)

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Etanercept in psoriasis: the evidence of its therapeutic impact
por: Thomson, Andrew
Publicado: (2007)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
por: Liao, Qibin, et al.
Publicado: (2020)

Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia
por: Hong, Fei, et al.
Publicado: (2021)

Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
por: Shima, Haruko, et al.
Publicado: (2021)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

Etanercept plus methotrexate: An effective combination therapy for recalcitrant pemphigus vulgaris
por: Andrés, Tirado-Sánchez, et al.
Publicado: (2015)

Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis
por: Hunter, Bradley D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q33u2hpgr3i7e21q5vtem411ue